Ascentage Pharma Group Internat
Every calculator, already run for AAPG
Open the full toolkit →You have the numbers on AAPG. Get the argument.
A written report on which of these readings actually decide the outcome for Ascentage Pharma Group Internat, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
8 analysts covering AAPGAnalyst Price Target Disagreement for Ascentage Pharma Group Internat
Wall Street's bull case implies +269% from the current price; the bear case implies +169%. A 101% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for AAPG
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Ascentage Pharma Group Internat
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL prote…
AAPG — frequently asked
Is AAPG a buy right now?
Wall Street's consensus rating on Ascentage Pharma Group Internat is Strong Buy across 8 analysts, with a mean price target of $47.13 (+216% vs. the current $14.89). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Ascentage Pharma Group Internat?
Analysts covering Ascentage Pharma Group Internat (AAPG) range from a bear-case target of $40.00 to a bull-case high of $55.00, with a mean consensus target of $47.13 across 8 analysts. The spread of $15.00 (101% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Ascentage Pharma Group Internat against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Ascentage Pharma Group Internat
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full AAPG research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Ascentage Pharma Group Internat, in minutes. 3 free reports included with every account — no credit card required.